Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus panitumumab vs chemoradiotherapy in unresected locally advanced squamous cell carcinoma of the head and neck
2007-001438-15Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of panitumumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Amgen. Primary endpoint: Local-regional control rate at 2 years. Started Jul 2007; status: completed.
02
Drugs
panitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2007-001438-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001438-15.